Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288545 · ClinicalTrials.gov registry record · Phase 1
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
A Phase 1 study of Urothelial Cancer and Urinary Bladder Neoplasms, sponsored by Astellas Pharma Global Development.
- Active
- Registry status
- Phase 1
- Development phase
- 348
- Enrollment target
- 20
- Study locations
NCT03288545 is a Phase 1 study of Urothelial Cancer and Urinary Bladder Neoplasms that is active but no longer recruiting, run by Astellas Pharma Global Development. The registered enrollment target is 348 participants, below the 561-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT03288545, a Phase 1 study of Urothelial Cancer and Urinary Bladder Neoplasms, is active but no longer recruiting, sponsored by Astellas Pharma Global Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 348 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG cisplatin
- DRUG carboplatin
- DRUG gemcitabine
- DRUG enfortumab vedotin (EV)
Study Locations (20)
California
- Tower Hematology Oncology Medical Group - Beverly Hills
- UC San Diego / Moores Cancer Center - La Jolla
- University of California Irvine - Newport - Orange
- University of California, Davis Comprehensive Cancer Center - Sacramento
- University of California at San Francisco - San Francisco
- Saint Joseph Heritage Medical Group - Santa Rosa
- Stanford Cancer Center / Blood & Marrow Transplant Program - Stanford
- Kaiser Permanente Southern California - Woodland Hills
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Arizona - Phoenix
- Arizona Oncology Associates, PC - HOPE - Tucson
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
- University of Colorado Hospital / University of Colorado - Aurora
Connecticut
- Yale Cancer Center - New Haven
- Eastern CT Hematology and Oncology Associates - Norwich
Florida
- Boca Raton Regional Hospital / Lynn Cancer Institute - Boca Raton
- Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center - Fort Lauderdale
Alaska
- Alaska Urological Institute - Anchorage
Arkansas
- Highlands Oncology Group - Fayetteville
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2026-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03288545
The ClinicalTrials.gov registry entry for NCT03288545 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 561-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (38% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Urothelial Cancer appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT03288545 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03288545 about?
NCT03288545 is a clinical study titled "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer". This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cance...
What is the current status of trial NCT03288545?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 348 participants. The study started on 2017-10-11. Estimated completion is 2026-09-11.
What conditions does trial NCT03288545 study?
This clinical trial studies the following conditions: Urothelial Cancer, Urinary Bladder Neoplasms, Urologic Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms.
What interventions are being tested in trial NCT03288545?
The interventions under investigation include: pembrolizumab (DRUG), cisplatin (DRUG), carboplatin (DRUG), gemcitabine (DRUG), enfortumab vedotin (EV) (DRUG).
Who is sponsoring clinical trial NCT03288545?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03288545 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Govitecan Plus EV in Metastatic UC
RECRUITING · Phase 1
-
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RECRUITING · Phase 1
-
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
RECRUITING · Phase 1
-
SLV-154 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RECRUITING · Phase 1
-
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.